Back to top
more

Cardlytics (CDLX)

(Delayed Data from NSDQ)

$11.52 USD

11.52
813,084

-0.85 (-6.87%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $11.53 +0.01 (0.09%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (152 out of 252)

Industry: Technology Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Cardlytics (CDLX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cardlytics (CDLX) delivered earnings and revenue surprises of 44.19% and 10.30%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Spotify (SPOT) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Spotify (SPOT) delivered earnings and revenue surprises of -111.25% and 2.28%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Cardlytics (CDLX) Surges 13.2%: Is This an Indication of Further Gains?

by Zacks Equity Research

Cardlytics (CDLX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

CleanSpark (CLSK) Soars 8.6%: Is Further Upside Left in the Stock?

by Zacks Equity Research

CleanSpark (CLSK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Is Cardlytics (CDLX) Stock Outpacing Its Business Services Peers This Year?

by Zacks Equity Research

Here is how Cardlytics (CDLX) and Trane Technologies (TT) have performed compared to their sector so far this year.

Does Cardlytics (CDLX) Have the Potential to Rally 49.25% as Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 49.3% upside potential for Cardlytics (CDLX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Cardlytics (CDLX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cardlytics (CDLX) delivered earnings and revenue surprises of 37.50% and 4.52%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Cardlytics (CDLX) Recently Broke Out Above the 200-Day Moving Average

by Zacks Equity Research

Should investors be excited or worried when a stock crosses above the 200-day simple moving average?

Earnings Preview: NV5 Global (NVEE) Q1 Earnings Expected to Decline

by Zacks Equity Research

NV5 (NVEE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Cardlytics (CDLX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Cardlytics (CDLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cardlytics (CDLX) Soars 80.9%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Cardlytics (CDLX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Strength Seen in Symbotic Inc. (SYM): Can Its 9.5% Jump Turn into More Strength?

by Zacks Equity Research

Symbotic Inc. (SYM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Cardlytics (CDLX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Cardlytics (CDLX) delivered earnings and revenue surprises of 45.28% and 2.16%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Cardlytics (CDLX): Can Its 12.1% Jump Turn into More Strength?

by Zacks Equity Research

Cardlytics (CDLX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Here's Why Cardlytics (CDLX) Is a Great 'Buy the Bottom' Stock Now

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Cardlytics (CDLX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

After Plunging 52% in 4 Weeks, Here's Why the Trend Might Reverse for Cardlytics (CDLX)

by Zacks Equity Research

Cardlytics (CDLX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Cardlytics (CDLX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Cardlytics (CDLX) delivered earnings and revenue surprises of 7.41% and 2.97%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Cardlytics (CDLX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Cardlytics (CDLX) delivered earnings and revenue surprises of -20.37% and 1.59%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Cardlytics (CDLX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cardlytics (CDLX) delivered earnings and revenue surprises of 44.93% and 3.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Seagate (STX) Misses Q3 Earnings Estimates

by Zacks Equity Research

Seagate (STX) delivered earnings and revenue surprises of -3.21% and 0.92%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Cardlytics (CDLX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cardlytics (CDLX) delivered earnings and revenue surprises of 63.41% and 16.64%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Copart, Inc. (CPRT) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Copart, Inc. (CPRT) delivered earnings and revenue surprises of 5.77% and 10.24%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?

Cardlytics (CDLX) Soars 6.2%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Cardlytics (CDLX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Cardlytics (CDLX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cardlytics (CDLX) delivered earnings and revenue surprises of 34.00% and 4.14%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Cardlytics (CDLX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Cardlytics (CDLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.